Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Tightly control drug abuse: a comprehensive upgrade in the regulation of addictive medicines such as Pregabalin and Yumei preparations
Today, the National Medical Products Administration (NMPA) learned that the NMPA, the Ministry of Public Security, and the Office of the National Narcotics Control Commission have jointly issued a new notice, which will further strengthen the full-chain regulation of addictive drugs such as pregabalin oral monotherapy preparations and Yumei preparations, resolutely curbing the spread of drug abuse.
The latest notice focuses on the production, circulation, and retail of drugs like pregabalin, implementing strict controls across all links.
The NMPA requires provincial drug supervision departments to strictly follow production plans to reduce abuse risks at the source; at the same time, it calls for comprehensive regulation of purchasing and sales behaviors, banning online retail or disguised retail of related drugs.
Physical retail outlets must sell products through dedicated counters and personnel, strictly based on prescriptions, with purchase and sale records kept in dedicated registers.
Record-keeping must include at least the drug name, specifications, sales quantity, manufacturing enterprise, batch number, purchase date, buyer’s name, and ID number.
(CCTV News)